Gray unit (Gy)
The unit of radiation dose absorbed by tissue: one gray is one joule per kilogram. A curative course is typically 50-70 Gy in total; a single bone-pain treatment is 8 Gy. Radiopharmaceuticals are prescribed by activity in becquerels (GBq) instead.
Overview
Because biological effect depends on both total dose and dose per fraction, different schedules are compared with the equivalent dose in 2 Gy fractions (EQD2) or biologically effective dose (BED); cervical brachytherapy aims for ≥85 Gy EQD2, early lung SBRT for BED ≥100 Gy. Dose escalation beyond 60 Gy did not help in stage III lung cancer (RTOG 0617) but did in prostate cancer. For radioligand therapy the administered activity (7.4 GBq of 177Lu-PSMA-617) is fixed, and dosimetry estimates the resulting gray to tumour and kidneys. Whole-body doses above about 4 Gy are lethal without marrow rescue, which is the basis of total body irradiation conditioning.
- PSMA / SSTR-positive cell
Showing the technology this term belongs to: Radioligand therapy (beta emitters).
Similar pages
not linked directly; found by shared links- IdeaTotal-body PET for personalised radioligand dosing
Shares Fixed versus personalised (dosimetry-guided) dosing, Dosimetry roadmap: MIRD schema → fixed dosing → personalised, image-based dose, Dosimetry, Radioligand therapy (beta emitters).
- IdeaDosimetry-personalised PRRT instead of four fixed cycles
Shares Fixed versus personalised (dosimetry-guided) dosing, Dosimetry roadmap: MIRD schema → fixed dosing → personalised, image-based dose, Dosimetry, Lutetium-177.
- TermCytopenias and myelosuppression
Shares Renal protection with amino acid co-infusion, Lutetium-177.
- InstitutionSahlgrenska University Hospital / Sahlgrenska Center for Cancer Research
- Agent177Lu-edotreotide
Shares Renal protection with amino acid co-infusion, Fixed versus personalised (dosimetry-guided) dosing, Radioligand therapy (beta emitters), Lutetium-177.
- CollectionOpenDose
Shares Dosimetry, Lutetium-177.
- TechnologyAuger-electron therapy
Shares Dosimetry, Radioligand therapy (beta emitters), Lutetium-177.
- IdeaAlpha-emitting PSMA therapy at first metastatic diagnosis
Shares Dosimetry, Radioligand therapy (beta emitters), Lutetium-177.